Labcorp, a renowned global life sciences company, brings together diagnostic testing and drug development to provide comprehensive healthcare solutions. Labcorp acquired Litholink in 2006, a leading provider of targeted testing for better management and prevention of chronic diseases such as kidney stones and chronic kidney disease. With sophisticated algorithms and a commitment to quality, Litholink offers 24-hour urine testing for kidney stone prevention.

Their services provide physicians with valuable treatment information, enabling better disease management. Through their innovative approach, Labcorp helps healthcare professionals deliver targeted care and improve patient outcomes. In 2023, Litholink publicly rebranded as Labcorp, solidifying their commitment to enhancing healthcare worldwide.

With a wide range of specialty testing groups, including chemical testing, clinical trials, and pathology, Labcorp offers an extensive menu of tests and services to meet diverse healthcare needs. Experience excellence in diagnostics and drug development with Labcorp